Oral Estrogen Replacement Therapy in Postmenopausal Women Selectively Raises Levels and Production Rates of Lipoprotein A-I and Lowers Hepatic Lipase Activity Without Lowering the Fractional Catabolic Rate

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 3, 1996, Pages 431-440

  Brinton, Eliot A ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Ethinyl estradiol; HDL; Hepatic lipase; Postmenopausal women; Turnover kinetics

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; CHOLESTEROL; ESTROGEN; ETHINYLESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LIPOPROTEIN A1; LIPOPROTEIN A2; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATHEROGENESIS; CATABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME ACTIVITY; ESTROGEN THERAPY; FEMALE; HUMAN; HUMAN EXPERIMENT; LIPOPROTEIN METABOLISM; LOW FAT DIET; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; TURNOVER TIME;

ADMINISTRATION, ORAL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LIPASE; LIPOPROTEIN LIPASE; LIPOPROTEIN(A); LIPOPROTEINS, HDL; LIVER; MIDDLE AGED; POSTMENOPAUSE;

EID: 0029866535     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.3.431     Document Type: Article

References (45)

1. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975;1:16-19.
2. Schaefer EJ, Foster DM, Zech LA, Lindgren FT, Brewer HB, Levy RI. The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab. 1983;57:262-267.
3. Hazzard WR, Haffner SM, Kushwaha RS, Applebaum-Bowden D, Foster DM. Preliminary report: kinetic studies on the modulation of high-density lipoprotein, apolipoprotein, and subfraction metabolism by sex steroids in a postmenopausal woman. Metabolism. 1984;33:779-784.
4. Applebaum-Bowden D, McLean P, Steinmetz A, Fontana D, Matthys C, Warnick GR, Cheung M, Albers JJ, Hazzard WR. Lipoprotein, apolipoprotein, and lipolytic enzyme changes following estrogen administration in postmenopausal women. J Lipid Res. 1989;30:1895-1906.
5. Colvin PL, Auerbach BJ, Case LD, Hazzard WR, Applebaum-Bowden D. A dose-response relationship between sex hormone-induced change in hepatic triglyceride lipase and high-density lipoprotein cholesterol in postmenopausal women. Metabolism. 1991;40:1052-1056.
6. Walsh BW, Li H, Sacks FM. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. J Lipid Res. 1994;35:2083-2093.
7. Shurtleff D. Some characteristics related to the incidence of cardiovascular disease and death: Framingham Study, 16-year follow up. In: Kannel WB, Gordon T, eds. The Framingham Study, an Epidemiological Investigation of Cardiovascular Disease. Section 26. Washington, DC: US Government Printing Office; 1970.
8. Witteman JCM, Grobbee DE, Kok FJ, Hofman A, Valkenburg HA. Increased risk of atherosclerosis in women after the menopause. BMJ. 1989;298:642-644.
9. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373-381.
10. Quintao ECR, Nakandakare E, Oliveira HCF, Rocha JC, Garcia RC, de Melo NR. Oral estradiol-17β raises the level of plasma high-density lipoprotein in menopausal women by slowing down its clearance rate. Acta Endocrinol. 1991;125:657-661.
11. Cheung MC, Albers JJ. Characterization of lipoprotein particles isolated by immunoaffinity chromatography. J Biol Chem. 1984;259:12201-12209.
12. Barbaras R, Puchois P, Fruchart J-C, Ailhaud G. Cholesterol efflux from cultured adipose cells mediated by LpAI particles but not by LpAI:II particles. Biochem Biophys Res Commun. 1987;142:63-69.
13. Barkia A, Puchois P, Ghalim N, Torpier G, Barbaras R, Ailhaud G, Fruchart J-C. Differential role of apolipoprotein A-I containing particles in cholesterol efflux from adipose cells. Atherosclerosis. 1991;87:135-146.
14. Puchois P, Kandoussi A, Fievet P, Fourrier JL, Bertrand M, Koren E, Fruchart JC. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis. 1987;68:35-40.
15. Coste-Burel M, Mainard F, Chivot L, Anget JL, Madec Y. Study of lipoprotein particles LpA-I and LpA-I:A-II in patients before coronary bypass surgery. Clin Chem. 1990;36:1889-1891.
16. Cheung MC, Brown BG, Wolf AC, Albers JJ. Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease. J Lipid Res. 1991;32:383-394.
17. Rader DJ, Ikewaki K, Duverger N, Feuerstein I, Zech L, Connor W, Brewer HB. Very low high-density lipoproteins without coronary atherosclerosis. Lancet. 1993;342:1455-1458.
18. Schultz JR, Verstuyft JG, Gong EL, Nichols AV, Rubin EM. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature. 1993;365:762-764.
19. Warden CH, Hedrick CC, Qiao J-H, Castellani LW, Lusis AJ. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science. 1993;261:469-472.
20. Rader DJ, Castro G, Zech LA, Fruchart J-C, Brewer HB. In vivo metabolism of apolipoprotein A-I on high density lipoprotein particles LpA-I and LpA-I, A-II. J Lipid Res. 1991;32:1849-1859.
21. Shepherd J, Packard CH, Gotto AM, Taunton OD. A comparison of two methods to investigate the metabolism of human apolipoproteins A-I and A-II. J Lipid Res. 1978;19:656-661.
22. Horowitz BS, Goldberg U, Merab J, Vanni TM, Ramakrishnan R, Ginsberg HN. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein AI in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest. 1993;91:1743-1752.
23. Parra HJ, Mezdour H, Ghalim N, Bard JM, Fruchart JC. Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates. Clin Chem. 1990;36:1431-1435.
24. Ikewaki K, Zech LA, Kindt M, Brewer HB, Rader DJ. Apolipoprotein A-II production rate is a major factor regulating the distribution of apolipoprotein A-I among HDL subclasses LpA-I and LpA-I:A-II in normolipidemic humans. Arterioscler Thromb Vasc Biol 1995;15:306-312.
25. Clay MA, Newnham HH, Barter PJ. Hepatic lipase promotes a loss of apolipoprotein A-I from triglyceride-enriched human high density lipoproteins during incubation in vitro. Arterioscler Thromb. 1991;11:415-422.
26. Cheung MC, Wolf AC, Knopp RH, Foster DM. Protein transfer between apo A-I containing lipoprotein subpopulations: evidence of nontransferable apo A-I in particles with apo A-II. Biochim Biophys Acta. 1992;1165:68-77.
27. Thuren T, Wilcox RW, Sisson P, Waite M. Hepatic lipase hydrolysis of lipid monolayers. J Biol Chem. 1991;266:4853-4861.
28. Harris JA, Benedict FG. A Biometric Study of Basal Metabolism in Man. Philadelphia, Pa: JB Lippincott Co; 1919.
29. Bilheimer DW, Eisenberg S, Levy RI. The metabolism of very low density lipoprotein proteins, I: preliminary in vitro and in vivo observations. Biochim Biophys Acta. 1972;260:212-221.
30. Verdery RB, Benham DR, Baldwin HL, Goldberg AP, Nichols AV. Measurement of normative HDL subfraction cholesterol levels by Gaussian summation analysis of gradient gels. J Lipid Res. 1989;30:1085-1095.
31. Manual of Laboratory Operations: Lipid Research Clinics Program, Vol 1, Lipid and Lipoprotein Analysis. Bethesda, Md: National Heart and Lung Institute, National Institutes of Health. 1974, revised 1982. US Department of Health, Education, and Welfare publication No NIH75-628.
32. Gidez LI, Miller GJ, Burstein M, Slagle S, Eder HA. Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res. 1982;23:1206-1223.
33. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of the preparative centrifuge. Clin Chem. 1972;18:499-502.
34. Brinton EA, Eisenberg S, Breslow J. Elevated high density lipoprotein cholesterol levels correlate with decreased apolipoprotein A-I and A-II fractional catabolic rate in women. J Clin Invest. 1989;84:262-269.
35. Schaefer EJ, Zech LA, Jenkins LL, Bronzert TJ, Rubalcaba EA, Lindgren FT, Aamodt RL, Brewer HB. Human apolipoprotein A-I and A-II metabolism. J Lipid Res. 1982;23:850-862.
36. Markwell MAK. A new solid-state reagent to iodinate proteins. Anal Biochem. 1982;125:427-432.
37. Shepherd J, Bedford DK, Morgan HG. Radioiodination of human low density lipoprotein: a comparison of four methods. Clin Chim Acta. 1976;66:97-109.
38. Eisenberg S. High density lipoprotein metabolism. J Lipid Res. 1984;25:1017-1058.
39. Saku K, Gartside PS, Hynd BA, Mendoza SG, Kashyap ML. Apolipoprotein AI and AII metabolism in patients with primary high-density lipoprotein deficiency associated with familial hypertriglyceridemia. Metabolism. 1985;34:754-764.
40. Brinton EA, Eisenberg S, Breslow JL. Increased Apo A-I and Apo A-II fractional catabotic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J Clin Invest. 1991;87:536-544.
41. Brinton EA, Eisenberg S, Breslow JL. A low-fat diet decreases high density lipoprotein (HDL) cholesterol levels by decreasing HDL apolipoprotein transport rates. J Clin Invest. 1990;85:144-151.
42. Brinton EA, Eisenberg S, Breslow JL. Human HDL cholesterol levels are determined by apo A-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Arterioscler Thromb. 1994;14:707-720.
43. Mokuno H, Yamada N, Shimano H, Ishibashi S, Mori N, Takahashi K, Oka T, Yoon TH, Takaku F. The enhanced cellular uptake of very-low-density lipoprotein enriched in apolipoprotein E. Biochim Biophys Acta. 1991;1082:63-70.
44. Kushwaha RS, Foster DM, Barrett PHR, Carey KD, Bernard MG. Metabolic regulation of plasma apolipoprotein E by estrogen and progesterone in the baboon (Papio sp). Metabolism. 1991;40:93-100.
45. Haffner SM, Kushwaha RS, Foster DM, Applebaum-Bowden D, Hazzard WR. Studies on the metabolic mechanism of reduced HDLs during anabolic steroid therapy. Metabolism. 1983;32:413-420.